NCCN VERSION 2 2015

176 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-101
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
intergroup trial (E1193). J Clin Oncol 2003;21:588-592. Available at:
.
464. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy
for metastatic breast cancer: a systematic review and meta-analysis of
randomized clinical trials. J Clin Oncol 2011;29:2144-2149. Available at:
.
465. Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative
Oncology Group randomized trials of observation versus maintenance
therapy for patients with metastatic breast cancer in complete remission
following induction treatment. J Clin Oncol 1998;16:1669-1676.
Available at:
466. Muss HB, Case LD, Richards F, et al. Interrupted versus
continuous chemotherapy in patients with metastatic breast cancer. The
Piedmont Oncology Association. N Engl J Med 1991;325:1342-1348.
Available at:
467. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy
versus treatment of physician's choice in patients with metastatic breast
cancer (EMBRACE): a phase 3 open-label randomised study. Lancet
2011;377:914-923. Available at:
.
468. Kaufman P, Awada A, Twelves C, et al. A phase III, open-label,
randomized, multicenter study of eribulin mesylate versus capecitabine
in patients with locally advanced or metastatic breast cancer previously
treated with anthracyclines and taxanes [abstract]. Cancer Res
2012;72( Suppl 24):Abstract S6-6. Available at:
eetingAbstracts/S6-6.
469. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of
ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy
in patients with metastatic breast cancer previously treated with
anthracycline chemotherapy. J Clin Oncol 2007;25:3415-3420.
Available at: .
470. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of
ixabepilone (BMS-247550), an epothilone B analog, in patients with
taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-
3406. Available at:
471. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of
ixabepilone (BMS-247550) in a phase II study of patients with advanced
breast cancer resistant to an anthracycline, a taxane, and capecitabine.
J Clin Oncol 2007;25:3407-3414. Available at:
.
472. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab
versus paclitaxel alone for metastatic breast cancer. N Engl J Med
2007;357:2666-2676. Available at:
.
473. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab
plus docetaxel compared with placebo plus docetaxel for the first-line
treatment of human epidermal growth factor receptor 2-negative
metastatic breast cancer. J Clin Oncol 2010;28:3239-3247. Available at:
.
474. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized,
double-blind, placebo-controlled, phase III trial of chemotherapy with or
without bevacizumab (B) for first-line treatment of HER2-negative locally
recurrent or metastatic breast cancer (MBC) [abstract]. J Clin Oncol
2009;27(Suppl 15):Abstract 1005. Available at:
.
475. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized,
double-blind, placebo-controlled, phase III trial of chemotherapy with or
without bevacizumab for first-line treatment of human epidermal growth
factor receptor 2-negative, locally recurrent or metastatic breast cancer.
J Clin Oncol 2011;29:1252-1260. Available at:
.
476. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of
overall survival data from three randomized trials of bevacizumab (BV)